Compare Global X FTSE Southeast Asia ETF (ASEA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Novo Nordisk A/S — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.43, while Novo Nordisk A/S trades at $45.88 (market cap $202.59B). The key difference: Novo Nordisk A/S pays a 3.87% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| ASEA | NVO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $21.53 | $63.98 |
52-Week Low | $16.86 | $35.29 |
Market Cap | — | $202.59B |
Enterprise Value | — | $217.28B |
Dividend Yield | — | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $21.45 with a modest 0.23% daily gain, showing bullish technical momentum with strong moving average support. The company has announced a $0.41 dividend for H1-2026, indicating management confidence in cash flow stability. Technical indicators show the stock is approaching resistance at $22 with strong trend momentum.
The stock presents a bullish technical setup near key resistance levels, though fundamental data remains limited. Dividend payments provide income appeal, but investors require updated financial metrics for comprehensive valuation assessment. Near-term price action will test the $22 resistance zone.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
